Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled pilot study of quilizumab in patients with refractory chronic spontaneous urticaria (CSU).

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled pilot study of quilizumab in patients with refractory chronic spontaneous urticaria (CSU).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quilizumab (Primary)
  • Indications Urticaria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 16 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 13 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Dec 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2013-003233-15).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top